Procurement Summary
Country : USA
Summary : In Vitro Assessments of Antimicrobial Activity
Deadline : 24 Apr 2025
Other Information
Notice Type : Tender
TOT Ref.No.: 117546298
Document Ref. No. : 75N93024R00024
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
AMENDMENT THREE
The purpose of Amendment Three is to:
1. Provide a cut-off date for submission of questions;2. Provide a new deadline for proposal submissions to eCPS;3. Provide an updated SBCx (small business subcontract plans) link; and4. Respond to questions received regarding this solicitation.
______________________________________________________________________
AMENDMENT TWO
The purpose of Amendment Two is to:
1. Respond to questions received regarding this solicitation.
______________________________________________________________________
AMENDMENT ONE
The purpose of Amendment One is to:
1. Provide a cut-off date for submission of questions;2. Provide updated instructions for the Proposal Intent Response Sheet;3. Clarify submission instructions to eCPS; and4. Respond to questions received regarding this solicitation.
______________________________________________________________________
Introduction
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement to support in vitro testing assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases.
Description
NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The current solicitation addresses a critical stage in this pipeline b...
Active Contract Opportunity
Notice ID : 75N93024R00024
Related Notice : 75N93024R00024
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office: NATIONAL INSTITUTES OF HEALTH NIAID
General Information
Contract Opportunity Type: Solicitation (Updated)
Updated Published Date: Apr 10, 2025 09:47 am EDT
Original Published Date: Dec 30, 2024 11:50 am EST
Updated Date Offers Due: Apr 24, 2025 03:00 pm EDT
Original Date Offers Due: Mar 10, 2025 03:00 pm EDT
Inactive Policy: 15 days after date offers due
Updated Inactive Date: May 09, 2025
Original Inactive Date: Mar 25, 2025
Initiative: None
Classification
Original Set Aside:
Product Service Code: AN11 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Place of Performance: Bethesda, MD USA
Documents
Tender Notice
Amendment-Three.pdf
Amendment-Two.pdf
Amendment-One.pdf
RFP-75N93024R00024.pdf
Attachment-1-Packaging-and-Delivery-of-Proposals.pdf
Attachment-3-Base-IDIQ-Statement-of-Work.pdf
Attachment-4-Sample-Task-Order-A-01.pdf
Attachment-5-Sample-Task-Order-A-02.pdf
Attachment-6-Sample-Task-Order-B-01.pdf
Attachment-7-Sample-Task-Order-C-01.pdf
Attachment-8-Sample-Task-Order-D-01.pdf
Attachment-10-Technical-Proposal-Cost-Summary.pdf
Attachment-11-Summary-of-Related-Activities.pdf
Attachment-12-Additional-Technical-Proposal-Inst.pdf
Attachment-13-Additional-Business-Proposal-Instr.pdf
Attachment-14-Proposal-Summary-and-Data-Record.pdf
Attachment-15-HHS-Industry-User-Guide-for-Subcon.pdf
Attachment-17-Offeror-Points-of-Contact.pdf
Attachment-18-Disclosure-of-Lobbying-Activities.pdf
Attachment-19-NIH-RC-4.pdf
Attachment-20-NIH-RC-2.pdf
Attachment-21-Safety-and-Health-HHSAR-352.pdf